RENAISSANCE
A multi-centre, non-interventional study of RElugolix as aNdrogen-deprivAtion therapy In patientS with advanced hormone-Sensitive prostate cANCEr
Description: The study is designed to better understand the actual experience of patients with prostate cancer treated with relugolix by collecting data on treatment patterns, effectiveness, persistence and adherence. Patients will be followed prospectively for up to one year from the date of signed informed consent (enrolment) in order to ascertain patient outcomes for this time period.
The goal of this study is to generate real word evidence from Europe about the population, effectiveness, and persistence of relugolix treatment in patients with advanced hormone-sensitive prostate cancer and their clinical course during treatment.
Study Phase: Other
Principal Investigator: Ms Louise McLoughlin
Further information